91 related articles for article (PubMed ID: 18396405)
41. SPRY domain-containing SOCS box protein 2: crystal structure and residues critical for protein binding.
Kuang Z; Yao S; Xu Y; Lewis RS; Low A; Masters SL; Willson TA; Kolesnik TB; Nicholson SE; Garrett TJ; Norton RS
J Mol Biol; 2009 Feb; 386(3):662-74. PubMed ID: 19154741
[TBL] [Abstract][Full Text] [Related]
42. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7.
Dell K; Klein C; Gissmann L
Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528
[TBL] [Abstract][Full Text] [Related]
43. Genetic diversity of human papillomavirus type 16 E6, E7, and L1 genes in Italian women with different grades of cervical lesions.
Cento V; Ciccozzi M; Ronga L; Perno CF; Ciotti M
J Med Virol; 2009 Sep; 81(9):1627-34. PubMed ID: 19626616
[TBL] [Abstract][Full Text] [Related]
44. E2 and the co-activator p300 can cooperate in activation of the human papillomavirus type 16 early promoter.
Krüppel U; Müller-Schiffmann A; Baldus SE; Smola-Hess S; Steger G
Virology; 2008 Jul; 377(1):151-9. PubMed ID: 18495195
[TBL] [Abstract][Full Text] [Related]
45. Transcription factor human Skn-1a enhances replication of human papillomavirus DNA through the direct binding to two sites near the viral replication origin.
Kukimoto I; Mori S; Sato H; Takeuchi T; Kanda T
FEBS J; 2008 Jun; 275(12):3123-35. PubMed ID: 18479461
[TBL] [Abstract][Full Text] [Related]
46. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
[TBL] [Abstract][Full Text] [Related]
47. Affilin molecules selected against the human papillomavirus E7 protein inhibit the proliferation of target cells.
Mirecka EA; Hey T; Fiedler U; Rudolph R; Hatzfeld M
J Mol Biol; 2009 Jul; 390(4):710-21. PubMed ID: 19464299
[TBL] [Abstract][Full Text] [Related]
48. Structure-based design and characterization of a Novel IL-6 antagonist peptide.
Yang Z; Feng J; Li Y; Hu M; Song L; Yu M; Qin W; Shen B
Mol Immunol; 2005 May; 42(9):1015-21. PubMed ID: 15829291
[TBL] [Abstract][Full Text] [Related]
49. Direct activation of caspase 8 by the proapoptotic E2 protein of HPV18 independent of adaptor proteins.
Thierry F; Demeret C
Cell Death Differ; 2008 Sep; 15(9):1356-63. PubMed ID: 18421300
[TBL] [Abstract][Full Text] [Related]
50. Thiocolchicine-podophyllotoxin conjugates: dynamic libraries based on disulfide exchange reaction.
Danieli B; Giardini A; Lesma G; Passarella D; Peretto B; Sacchetti A; Silvani A; Pratesi G; Zunino F
J Org Chem; 2006 Mar; 71(7):2848-53. PubMed ID: 16555841
[TBL] [Abstract][Full Text] [Related]
51. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
52. Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study.
Collins SI; Constandinou-Williams C; Wen K; Young LS; Roberts S; Murray PG; Woodman CB
Cancer Res; 2009 May; 69(9):3828-32. PubMed ID: 19401452
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of 4beta-[(4-substituted)-1,2,3-triazol-1-yl]podophyllotoxins as potential anticancer agents.
Reddy PB; Agrawal SK; Singh S; Bhat BA; Saxena AK; Kumar HM; Qazi GN
Chem Biodivers; 2008 Sep; 5(9):1792-802. PubMed ID: 18816530
[TBL] [Abstract][Full Text] [Related]
54. Phage display and crystallographic analysis reveals potential substrate/binding site interactions in the protein secretion chaperone CsaA from Agrobacterium tumefaciens.
Feldman AR; Shapova YA; Wu SS; Oliver DC; Heller M; McIntosh LP; Scott JK; Paetzel M
J Mol Biol; 2008 Jun; 379(3):457-70. PubMed ID: 18462752
[TBL] [Abstract][Full Text] [Related]
55. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
56. Application of artificial zinc-finger proteins to inhibition of DNA replication of human papillomavirus.
Mino T; Mori T; Matsumoto N; Mineta Y; Okamoto T; Aoyama Y; Sera T
Nucleic Acids Symp Ser (Oxf); 2006; (50):313-4. PubMed ID: 17150943
[TBL] [Abstract][Full Text] [Related]
57. CTL responses to a DNA vaccine encoding E7 gene of human papillomavirus type 16 from an Iranian isolate.
Meshkat Z; Soleimanjahi H; Mahmoudi M; Hassan ZM; Mirshahabi H; Meshkat M; Kheirandish M
Iran J Immunol; 2008 Jun; 5(2):82-91. PubMed ID: 18523353
[TBL] [Abstract][Full Text] [Related]
58. Development of protein-based antiviral drugs for human papillomaviruses.
Mino T; Mori T; Aoyama Y; Sera T
Nucleic Acids Symp Ser (Oxf); 2007; (51):427-8. PubMed ID: 18029769
[TBL] [Abstract][Full Text] [Related]
59. Cell-penetrating peptide-conjugated XIAP-inhibitory cyclic hexapeptides enter into Jurkat cells and inhibit cell proliferation.
Sasaki Y; Minamizawa M; Ambo A; Sugawara S; Ogawa Y; Nitta K
FEBS J; 2008 Dec; 275(23):6011-21. PubMed ID: 19016849
[TBL] [Abstract][Full Text] [Related]
60. Bovine papillomavirus type 1 E2 protein heterodimer is functional in papillomavirus DNA replication in vivo.
Kurg R; Uusen P; Sepp T; Sepp M; Abroi A; Ustav M
Virology; 2009 Apr; 386(2):353-9. PubMed ID: 19232665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
